Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STARLIGHT: 166Ho-Radioembolization + FTD-TPI + Bevacizumab in mCRC
NCT06563986Phase 2Recruiting
- Start
- Jun 2024
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial. Primary endpoint: Hepatic Objective Response Rate (PERCIST 1.0) at 1 year. Started Jun 2024; status: recruiting.
Beyond the preview
Go deeper on NCT06563986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06563986.